SEPRAFILM® and Abdominopelvic Surgeries

Hysterectomy

Prophylactic use of SEPRAFILM has been shown to reduce the incidence of adhesions and adhesion-related morbidities.1-5 In radical pelvic surgery, including hysterectomy, SEPRAFILM has been shown to reduce the extent of pelvic floor adhesions by 69% relative to historical controls.6

Hysterectomy

SEPRAFILM-treated pelvis at second look following radical oophorectomy.6

SEPRAFILM application sites in total abdominal hysterectomy7:

  • Vaginal cuff
  • Lymph node beds
  • Pelvic peritoneal defect
  • Abdominal sidewall
  • Under abdominal incision
  • Remaining adnexa

Myomectomy

In a prospective, randomized, double-blinded, multicenter controlled study of patients receiving SEPRAFILM at open myomectomy, SEPRAFILM reduced the incidence, severity, and extent of posterior and anterior uterine adhesions. Moreover, 48% of SEPRAFILM-treated patients were free of adhesions to at least one adnexum, compared to only 31% in the untreated control population.2

Myomectomy

SEPRAFILM application sites in myomectomy7:

  • Anterior uterus
  • Posterior uterus
  • Adnexa
  • Abdominal incision

Indication
Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy.

Important Safety Information
Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm has not been established in combination with other adhesion prevention products and/or in surgical procedures not within the abdominopelvic cavity. The safety and effectiveness of Seprafilm has also not been evaluated in cases of pregnancy, malignancy, or frank infection. The type and frequency of adverse events reported are consistent with events typically seen following abdominopelvic surgery when used as directed.

Please see full prescribing information.

Adhesions and abdominopelvic surgeries

Learn more about adhesive disease in hysterectomy and myomectomy.

Adhesive disease

What is SEPRAFILM?

Discover the science behind SEPRAFILM Adhesion Barrier.

The science

References:  1. Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183:297-306.  2. Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Fertil Sterility. 1996;66:904-910.  3. Fazio VW, Cohen Z, Fleshman JW, et al. Reduction in adhesive small-bowel obstruction by Seprafilm Adhesion Barrier after intestinal resection. Dis Colon Rectum. 2006;49:1-11.  4. Tang C-L, Seow-Choen F, Fook-Chong S, Eu K-W. Bioresorbable adhesion barrier facilitates early closure of the defunctioning ileostomy after rectal excision: a prospective, randomized trial. Dis Colon Rectum. 2003;46:1200-1207.  5. Kusunoki M, Ikeuchi H, Yanagi H, et al. Bioresorbable hyaluronate-carboxymethylcellulose membrane (Seprafilm) in surgery for rectal carcinoma: a prospective randomized clinical trial. Surg Today. 2005;35:940-945.  6. Bristow RE, Montz FJ. Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. Gynecol Oncol. 2005;99:301-308.  7. SEPRAFILM Adhesion Barrier Prescribing Information. Cambridge, MA: Genzyme Biosurgery; 2008.